Vir Biotechnology, Inc.
corporate_fare Company Profile
Vir Biotechnology, Inc. (NASDAQ:VIR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for VIR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VIR spans 8-K, 10-Q, 424B5, 10-K.
Recent high-impact activity:
- Q3 Loss Narrows to $96M as Vir Flags ECLIPSE 1 Data This Quarter
- Vir Bio Lands Gilead Collaboration With $90M Upfront and $25M Equity at 30% Premium
- Vir Inks $135M Upfront Deal with Gilead for Dual-Masked T-Cell Engagers
- FDA Grants Fast Track to Vir's VIR-5500 for Late-Line Prostate Cancer
- Vir Biotech Posts $80.1M Q2 Profit, 88% HDV Clearance in Key Trial
Financial Snapshot
Short Interest & Short Volume
6.92 days to coverFINRA reported short interest of 16,236,717 shares in VIR as of the October 15, 2026 settlement, a 8.4% increase from the prior period — about 6.9 days to cover at its recent average daily volume. On November 5, 2026, 64.0% of VIR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.